Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.
Delivering on our commitment to provide evidence and resources that support Canada’s response to the opioid crisis continues to be a key priority for CADTH.
Over the summer we’ve answered a range of research questions related to the treatment of opioid use disorder and the use of drug and non-drug interventions to manage pain. All of our reports...
A draft report on Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism is now available for feedback from all interested stakeholders.
Call for Feedback
Feedback Due By
Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism
Submit Stakeholder Feedback
Event Date: October 3, 2017Location: Beanfield Centre, Room 204 ABC
105 Princes’ Blvd., Toronto, ON
The CADTH Drug Portfolio Information Sessions are an opportunity to receive an update on our drug portfolio, including CADTH’s Common Drug Review (CDR), pan-Canadian Oncology Drug Review (pCODR), and Therapeutic Reviews. Updates on other relevant ...
CADTH has completed its Therapeutic Review update of second-line therapies for patients with type 2 diabetes. The following reports are now available on the CADTH website:
final science report on second-line therapy (clinical and economic evaluations)
final recommendations report on second-line therapy
In Brief — a summary ...